teaser
Shire plc, the global specialty biopharmaceutical company, today announced that it will present key scientific data on its attention deficit hyperactivity disorder (ADHD) treatments, lisdexamfetamine dimesylate (CII) and investigational nonscheduled guanfacine extended release, at a national scientific meeting of psychiatrists to be held on 16-21 May in San Francisco, CA.
“Shire is committed to the advancement of ADHD treatment research and eager to present results from a spectrum of studies,” said Jeffrey Jonas, MD, senior vice president of Research & Development for the specialty pharmaceuticals business at Shire. “We believe the lisdexamfetamine dimesylate and guanfacine extended release study findings to be presented will contribute greatly to the growing body of research and development for physicians in the field of ADHD.”
